Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROBO1 CAR-NK in Pancreatic Cancer
NCT03941457Phase 2Unknown
- Sponsor
- Asclepius Technology Group
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ROBO1 CAR-NK cells in pancreatic adenocarcinoma (PDAC), sponsored by Asclepius Technology Group. Primary endpoint: Occurrence of treatment related adverse events at 1 year. Status: unknown.
02
Drugs
ROBO1 CAR-NK cells
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03941457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941457.